医脉通（02192.HK）今日盘中股价大涨5.90%，引发市场广泛关注。截至发稿，该股报价15.120港元，成交量达305.8万股，换手率为0.42%。
此次股价上涨主要受到公司最新发布的2025年中期业绩报告的推动。根据8月25日披露的财报，医脉通2025年上半年实现营业收入3.12亿元，同比增长28.18%；归母净利润1.55亿元，同比增长5.87%。优异的业绩表现大大提振了投资者信心。此外，公司还宣布了每股0.1166元（相当于0.1277港元）的中期分红方案，进一步吸引了市场的目光。
值得注意的是，医脉通在资本市场上获得了较高的认可度。在4家参与评级的机构中，75%给予买入建议，25%给予持有建议，无券商给予卖出建议。这种积极的分析师评级也为股价上涨提供了支撑。同时，医脉通所在的医疗及医学美容服务行业整体表现稳健，今日涨幅为0.37%，进一步凸显了医脉通的优异表现。随着公司在精准营销、企业解决方案、医学知识解决方案等领域的持续发展，市场对其未来前景保持乐观态度。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.